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Summaゆ Comparativest1idy of combination of H2 blocker. and cytoprotective 
agents and H2 blocker alone in maintenance therapy was performed to evaluate its e血-
cacyin the' prevention uf the recurrence of gastric ulcer. 
For the purp~se， 136 patients wi，th endoscopical1y confirmed gastric br gastroduode-
nal ulcer were treated with one year maintenance by these drugs after healing. In the 
mainteni'lnce therapy， patieIlts were divided into two groups: Group H (patients who 
，w:ert: i'ldn1Inistered one of the H2 tlockers alone; cimetidine400 mg， ranitidine 150 mg 
，Or famotidine ~O.mg.， nocte) and Group HC (patients being treated with one of the 
H2 blockers and one of the cytoprotective agents; sucralfate 1 g， teprenone 50 mg' or a]・
dioxa 100mg 3 times a day in a combination regimen). During the maintenance ther-
apy， the lesions were observed every 3 months by endoscopy to check for recurrence and 
for the stage of ulcer scar for one year. 
1) Cumulative recurr百 lce開 freerate of Group HC was about 10% higher than出atof 
Group H during 12 months of maintena恥 etherapy. 2) In gastroduodena.l ulcer 
patients， recurrence幽 freerate of Group HC was significantly higher than that of Group 
H (p<O.OI). 3) In patients who had recurrent ulcer and who had ulcer that was healed 
within 3 months after treatment， the recurrence-free rate of Group' HC tended to be high-
er than that of Group H. 4) Inthese two groups， the recurrence-free rate of white ulcer 
scar was significantly higher than that of red ulcer scar (p<0.05). 
It is concluded that the maintenance therapy of combination regimen is more effec同
tive than that of H2 blocker alone and red ulcer scar is more likely to recur than 
white ulcer scar in spite of the combination maintenance therapy. This fact suggests that 





























































tidine 800 mgfday， ranitidine 300 mgfdayまたは famo開




強剤別に 3群に分け， sucralfate 4 mgfdayの分4 (毎
食間と就寝前)を併用した HS群， teprenone 150 mgf 
dayの分 3 (毎食後)を併用した HT群および aldoxa





cimetidine 400 mg， ramitidine 150 mgまたは famoti-
dine 20 mgの就寝前投与を行った.H群では防御因子
増強剤の併用は行わず， HC群の HS，HTおよび HA
群にはそれぞれ sucralfate3 g分 3 (毎食間)， tepre-
none 150 ing分 3 (毎食後)および aldioxa300 mg 
分 3 (毎食後)の l剤のみの併用を行った.
2) 観察方法
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Table 1. Methods of treatment and maintenance therapy 
group treatment maintenanc巴 therapy
H Hz blocker with or without Half theraputic dose of Hz blocker 
cytoprotective agents 
日C Hzblocker with Half theraputic dose of Hg blocker 
cytoprotective agents with cytoprotective agents 
Hg blocker: cimetidine 800 mg/day， ranitidine 300 mg/day 
or famotidine 40 mg/day 
Cytoprotective agents: sucralfate 3 g/day (group HS)， teprenone 150 mg/day 










































































Table 2. Patient characteristics 
日C
group H total X2 test 
HS HT HA total 
patients number 29 54 25 28 107 136 
sex male 23 [ 3.8J 39 19 21 79 [3.2J 102 [ 3.0J NS 
female 6 15 6 7 28 34 
age ~39 1 ( 3.4) 7 3 2 12 (11.2) 13 ( 9.6) 
40~49 10 (34.5) 12 5 5 22 (20.6) 32 (23.5) 
50~59 12 (41. 4) 17 B 8 33 (30.8) 45 (33.0) NS 
60~69 4 (13.8) 14 7 1 32 (29.9) 36 (26.5) 
70~ 2 ( 6.9) 4 2 2 8 ( 7.5) 10 ( 7.4) 
episode 五rst 9 (31. 0) 20 6 6 32 (29.9) 41 (30.2) 
NS 
relapse 20 (69.0) 34 19 22 75 (70. 1) 95 (69.8) 
u1cer number single 28 (96.6) 54 22 28 104(97.2) 132 (97.1) 
NS 
口:mtiple 1 ( 3.4) 。 3 O 3 ( 2.8) 4 ( 2.9) ， 
_ with d.u.(s.) yes 10 (34.5) 26 6 1 43 (40.2) 53 (39.0) 
NS 
no 19 (65.5) 28 19 17 64 (59.8) 83 (61. 0) 
smoking yes 18 (62. 1) 27 17 17 61 (57.0) 79 (58.1) 
NS 
no 1 (37.9) 27 8 1 46 (43.0) 57 (41. 9) 
: d.u.(s.) duodenal u1cer (scar) ]: ratio of male to female NS: not significant 
(%) 
Table 3. Characteristics of u1cers 
HC 
group 同 H total χ2 test 
E王S HT HA total 
number of lesions 30 54 28 28 110 140 
size (mm) ~5 6 (20.0) 12 8 1 31 (28.2) 38 (27. 1) 
6~ 1O 10 (33.3) 3，6 ， 13 14 63 (57.3) 85 (60.8) NS 
11~ 14 (46.7) 6 7 3 16 (14.5) 17 (12.1) 
u1cer stage A2 7(23.3) 1 7 3 21 (19.1) 27 (19.3) 
H1 22 (73.3) 26 8 7 41 (37.3) 51 (36.4) NS 
日2 1 (3.4) 17 13 18 48 (43.6) 62 (44.3) 
location corpus 1 (36.7) 17 1 12 40 (36.3) 51 (36.4) 
angulus 17 (56.6) 31 16 14 61 (55.5) 78 (55.7) NS 
antrum 2 ( 6.7) 6 2 9 ( 8.2) 1 ( 7.9) 
u1cer episode ~3 15 (50.0) 41 20 20 81 (73.6) 96 (68.6) 
NS 
duration (M) 4 ~ 15 (50.0) 13 8 8 29 (26.4) 44 (31. 4) 
scar red 22 (73.3) 30 21 20 71 (64.5) 93 (66.4) 
NS 
white 8(26.7)ι24 7 8 39 (35.5) 47 (33.6) 
(%) NS: not significant 
非:再発率に12カ月間を通して明らかな差はみられない られないが，胃・十二指腸併存潰湯例では90日 (Pく
(Fig.6). 0.05)， 210日 (Pく0.01)，300日 (Pく0.05)，および全期間
i)併存潰疹例 (Pく 0.01)において有意に併用群の方が単独群に比べて
胃単独潰療の場合は両群の累積非再発率に有意差はみ 高い累積非再発率を示していた (Fig.7，Fig.8). 
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一一 HS (n~54) 
ー.H (n胃 30)
z test 十 p~ 0.08 





Fig.4. Cumulative recurrenceイreerate in group 
日 andgroup HC. 












Fig. 1. Cumulativ巴 recurrence-freerate in group 
H and group HS. During one year main幽
tenance 'therapy， recurrence開free rate in 
group HC is higher than group H. Statis-
tical tendency is found in both groups 
(P=0.09). 






一←-HC (n ~ 80) 
・一..H (n~ 16) 
40 
generalzed WilcoXOh 十 p~ 0.06 
maintenance term 
Fig.5. Cumulative recurrenceイree rate in the 
ulcers that healed within 3 months of 
treatment. Cumulative recurrence-free rate 
of group HC is higher than group H 





一一 HT (門員 28)




Fig.2. Cumulative recurrence-free rate in group 








































40 一一 HC(n ~ 29) 
日 H (n ~ 14) 
60' 60 
一一-HA (n ~ 28) 





Fig. 6. Cumulative recurrence.仕eerate of retract-
able ulcer. No remarkable difference is 





Fig.3. Cumulativ;e recurrence圃 freerate in group 





































H (n ~ 19) 
12 (M) 
maintenance term 
Fig.7. Gastric ulcer only cases. There is no 


























トI (n~2 1) 
z tcst * P弓0.05
generalized Wilcoxon : t P = 0.06 
9 
maintenance term 
Fig.lO. Cumulative recurrence-free rate of recur-
rent ulcer. Recurrence-free rate in group 






































H (n~1 1) 
z test * Pく 0.05
generaliZl?d Wilcoxon : * * P< 0.01 12 (M) 
maintenance term 
Fig: 8. Gastroduodenal ulcer inchiding duodenal 
ulcer scar. RecurreI1ce-free rate in group 
















































一一_HC (n ~ 32) 
け (n~ 9) 
6 
malntenance term 
Fig. 11. Cumulative recurrence-free rate of the 
ulcer located in gastric angulus and 
antral portion. The recurrence幽freerate 
of both group is relative low. buf group 





Fig.9. Cumulative recurrenc・-efree ra te of pri帽
mary ulcer. Recurrence free rate in both 
group is relative high and there is no re司








































Fig. 15. The rccurrence rate in white ulcer scar 
anc¥ rcd ulcer scar in the maintenance 
therapy. Recurrence rate in red ulcer scar 
is tenc¥ to be higher than that of white 




Fig. 12. Cumulativ巴 rccurrence-freerate of the 
ulcerlocatec¥ in gastric boc¥y. Recurrence・t
free rate in both groups is relative 'hi匡h




。~3 inonths 4 ~l2 months 
recurence rate recurence rate 
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ー-HC (門誌 58)
。H (n ~ 19) 
























white scar 12 (M) 
mamtenance term 
3 
Fig.16. The recurrence rate was analized from 
a toint of maintenanc巴 term.All of the 
recurrence wereocurred in red ulcer scar 
lesion within 3 months from the beginn-
ing of， maintenance tl;1erapy. In both 
group， • recllrrence ra，te of red ulcer scar 
is significantry higher than that of white 
scar within 3 months of ~aintenance 
therapy. And recurrence rate of group 
E王istend to be higher than that of group 
HC. In 4 months to 12 months of main.圃
tenance therapy， there is no remarkable 
difference between red and white ulcer 
scar. 
十 p< 0，1 
* P < 0.05 Fig. 13. Cumulative recurrence-free rate of smoker 
patient. Cumulative recurrence-free rate 







































Fig. 14. Cumulative recurrence司freerate of non 
smoker patient. There is little difference 
between 2 groups. 





























































































































































































胃潰療に対する H2blockerと防御因子増強剤 (141 ) 
による併用維持療法の臨床効果に関する検討



























累積非再発率を有意に (Pく 0.01)高め， 3カ月以内に











S1 stageからの再発率が S2st五geに比べて有意に (P<
0.05)高率であった.
6) 維持療法 3カ月以内では全群共に再発はすべて
S1 stageからであり S2stageに比べて有意に (Pく 0.05)
高率であった.また，単独群は併用群に比べて S1stage 
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